相关实验视频
Updated: May 17, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
218
[德国肥胖的药物治疗]
1Helmholtz-Institut für Metabolismus‑, Adipositas- und Gefäßforschung (HI-MAG), Helmholtz Zentrum München an der Universität Leipzig und dem Universitätsklinikum Leipzig AöR, Philipp-Rosenthal-Straße 27, 04103, Leipzig, Deutschland. bluma@medizin.uni-leipzig.de.
Innere Medizin (Heidelberg, Germany)
|April 25, 2025
概括
药物治疗,包括新的基于基的药物,可显著减肥,并改善肥胖治疗的心脏代谢健康. 这些药物还治疗相关疾病,如2型糖尿病和高血压.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖症的治疗始于保守的多模式方法,如饮食,运动和行为改变.
- 当初始目标未实现时,药理疗支持基本治疗,旨在减肥,稳定和管理肥胖作为慢性疾病.
研究的目的:
- 审查药物治疗在全面肥胖治疗中的作用和影响.
- 为了突出最近基于英克雷的药物的好处和副作用.
- 讨论肥胖管理新兴药物治疗的潜力.
主要方法:
- 对目前肥胖的药物治疗选择的审查.
- 分析基于英克雷丁的药物 (利拉格卢提德,塞马格卢提德,蒂尔泽帕提德) 和它们的影响.
- 包括setmelanotide用于罕见的单一性肥胖症.
- 在临床开发中考虑药物.
主要成果:
- 基于因克雷的药物治疗表明显著减肥和心脏代谢益处.
- 这些药物可以改善与肥胖相关的并发症,如2型糖尿病,高血压和脂肪肝疾病.
- 轻度至中度的胃肠道副作用是基于英克雷丁的疗法常见的.
- 塞特梅拉诺提德可用于罕见的单一性肥胖形式.
结论:
- 新的药物治疗方法,特别是基于隐素的药物,显示出有效的肥胖管理的前景.
- 这些药物具有良好的疗效,副作用概况和心脏代谢益处.
- 新兴的治疗方法有可能显著提高药物治疗在德国肥胖症的重要性.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:28Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
130
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
130
01:24Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276
01:23Antidepressant Drugs: MAOIs and Other Agents
171
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
171